Live prices paused — reconnecting…
Mounjaro approved for heart failure?
Loading...
Market trust
Review trustProviderManual ReviewEvidenceNot ReadyManual source - last checked Not checked yet
Market trust
Review trustProviderManual ReviewEvidenceNot ReadyManual source - last checked Not checked yet
- Trust score
- In review
- Source type
- Manual
- Provider health
- Manual Review
- Criteria quality
- Warn
- Market data quality
- Review
- Public evidence state
- Not Ready
- Chart data provenance
- Drazill Market Data
- Price history freshness
- Fresh
- Last source check
- Not checked yet
Trust methodology
Formula: market-trust-v1.0
Window: Latest market, criteria, provider, and evidence records
Confidence: MEDIUM
Informational only, not trading advice.
- - Provider health is market-specific when resolution checks exist and otherwise inferred from configuration.
- - Manual-only markets rely on admin review rather than automated source polling.
31%
Yes
@ $0.31
69%
No
@ $0.69
Market open
May 5, 2026, 06:41 p.m.
Market closes
Feb 24, 2027, 06:41 p.m.
Projected payout
After market closes
About This Market
FDA, Eli Lilly tirzepatide by end of 2026. Resolves YES if the FDA approves tirzepatide (Mounjaro/Zepbound) for a heart failure indication before Jan 1, 2027. Source: FDA approval letters
Source
Official announcement or authoritative source
